Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

26.7%

4 terminated/withdrawn out of 15 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

8(53.3%)

Phase 1

5(33.3%)

Phase 3

1(6.7%)

Phase 4

1(6.7%)

15Total

Phase 2(8)

Phase 1(5)

Phase 3(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (15)

Showing 15 of 15 trials

NCT02641639Phase 2Terminated

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Role: lead

NCT05004753Phase 4Completed

A Study to Evaluate the Safety and Efficacy of Artemisinin- a Herbal Supplement on COVID-19 Subjects

Role: lead

NCT02055690Phase 1Terminated

PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer

Role: collaborator

NCT02576301Phase 1Unknown

Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS

Role: lead

NCT02279602Phase 2Completed

Rollover Protocol for Subjects Who Have Responded on Study 4218s - A Phase 2 Study

Role: lead

NCT02132468Phase 2Completed

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Role: lead

NCT00653939Phase 2Completed

A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer

Role: lead

NCT00507429Phase 2Terminated

Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer

Role: lead

NCT01701349Phase 3Withdrawn

Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer

Role: lead

NCT01423149Phase 2Completed

Safety and Efficacy Study of Combretastatin A4 Phosphate to Treat Patients With Choroidal Neovascularization Secondary to Pathologic Myopia

Role: lead

NCT01023295Phase 2Completed

Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV)

Role: lead

NCT00113438Phase 2Completed

Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors

Role: lead

NCT00395434Phase 1Completed

Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

Role: lead

NCT00977210Phase 1Completed

Safety Study of OXi4503 (a Vascular Disrupting Agent) Given by 3 x Weekly Intravenous Infusions to Patients With Advanced Solid Tumors

Role: lead

NCT00960557Phase 1Completed

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden

Role: lead

All 15 trials loaded